Literature DB >> 17123028

Combination pharmacotherapy in hypertension.

George S Stergiou1.   

Abstract

Combination pharmacotherapy with two or more drugs is required in order to reach the currently recommended blood pressure goals in the majority of hypertensive patients, particularly those with a goal of <130/80 mm Hg. Further to the potentiation of the antihypertensive effects, benefits of combination therapy include the potential of fewer adverse affects and of improvement of patients' compliance. Current guidelines recommend that combination pharmacotherapy might also be considered as initial treatment in patients with significant elevation of blood pressure and evidence of complications. Several effective and well-tolerated antihypertensive drug classes available today offer multiple options for combination therapy. The choice of antihypertensive agents should be made on the basis of current recommendations regarding first line drugs and compelling indications. Specific drug combinations might have additional beneficial or detrimental long-term metabolic effects, beyond their effects on blood pressure. However, more outcome data comparing antihypertensive drug combinations are required. The implementation of an intensive up-titration treatment strategy, together with a systematic use of full doses of multiple drug combinations, is expected to achieve optimal blood pressure control in the vast majority of hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123028     DOI: 10.1007/s11255-006-0036-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  58 in total

1.  Reserpine-hydralazine combination therapy of hypertensive disease, with hydralazine in doses generally below the toxic range.

Authors:  R E LEE; A M SELIGMANN; D GOEBEL; L A FULTON; M A CLARK
Journal:  Ann Intern Med       Date:  1956-03       Impact factor: 25.391

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Authors:  Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

5.  Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism?

Authors:  G S Stergiou; I I Skeva; N M Baibas; C B Kalkana; L G Roussias; T D Mountokalakis
Journal:  Am J Hypertens       Date:  2001-07       Impact factor: 2.689

6.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

Review 9.  Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.

Authors:  George S Stergiou; Irini I Skeva
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 10.  New European, American and International guidelines for hypertension management: agreement and disagreement.

Authors:  George S Stergiou; Eleanna V Salgami
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-05
View more
  1 in total

1.  Comparative effectiveness analysis of amlodipine/renin-angiotensin system blocker combinations.

Authors:  C Venkata S Ram; Joseph Vasey; Sumeet Panjabi; Chunlin Qian; Ruth Quah
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-13       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.